Portola Pharmaceuticals   Print Page    Close Window

Corporate Profile

Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. Our first commercial product, Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor anticoagulant, is approved in the United States. We are also advancing the clinical development of two ot... Read More

Stock Quote
NASDAQ PTLA (Common Stock)
$40.95 - 0.41
Stock chart for: PTLA.O.  Currently trading at $40.95 with a 52 week high of $67.10 and a 52 week low of $30.10.
05/21/18 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Upcoming EventsMore >>
There are currently no events scheduled.
Archived Events
Q1 2018 Portola Pharmaceuticals, Inc. Financial Results Conference Call
Wednesday, May 9, 2018 4:30 p.m. ET

Andexxa FDA Approval Call
Friday, May 4, 2018 8:30 a.m. ET